Assetmark, Inc Alkermes Plc. Transaction History

Assetmark, Inc

$47.4 Billion
Q4 2025

A detailed history of Assetmark, Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Assetmark, Inc holds 649 shares of ALKS stock, worth $18,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares

649

Previous 827 21.52%

Holding current value

$18,846

Previous $24,000 25.0%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 23, 2026	SELL	$29.04 - $33.81 $5,169 - $6,018	-178 Reduced 21.52%	649 $18,000
Q3 2025 Nov 06, 2025	BUY	$26.13 - $30.46 $19,519 - $22,753	747 Added 933.75%	827 $24,000
Q2 2025 Aug 04, 2025	BUY	$26.59 - $32.65 $1,941 - $2,383	73 Added 1042.86%	80 $2,000
Q4 2024 Feb 06, 2025	BUY	$25.7 - $31.46 $179 - $220	7 New	7 $0
Q3 2023 Oct 27, 2023	BUY	$27.17 - $31.97 $163 - $191	6 New	6 $0

Q1 2019 May 14, 2019	SELL	$28.4 - $36.49 $511 - $656	-18 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$27.94 - $44.61 $3,213 - $5,130	-115 Reduced 86.47%	18 $1,000
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $193 - $230	-5 Reduced 3.62%	133 $6,000
Q2 2018 Aug 01, 2018	BUY	$40.56 - $51.36 $567 - $719	14 Added 11.29%	138 $6,000
Q1 2018 May 16, 2018	BUY	$53.61 - $67.26 $2,251 - $2,824	42 Added 51.22%	124 $7,000
Q4 2017 Feb 13, 2018	SELL	$47.69 - $55.39 $47 - $55	-1 Reduced 1.2%	82 $4,000
Q3 2017 Nov 08, 2017	SELL	$49.16 - $54.45 $49 - $54	-1 Reduced 1.19%	83 $4,000
Q1 2017 Sep 15, 2017	BUY	N/A	2 Added 2.44%	84 $5,000
Q4 2016 Sep 15, 2017	SELL	N/A	-26 Reduced 24.07%	82 $5,000
Q3 2016 Sep 15, 2017	BUY	N/A	26 Added 31.71%	108 $5,000
Q1 2016 Sep 15, 2017	BUY	N/A	42 Added 105.0%	82 $3,000
Q4 2015 Sep 15, 2017	BUY	N/A	40	40 $3,000

Others Institutions Holding ALKS

# of Institutions

403

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account